- Product name:Retatrutide
- CAS NO:2381089-83-2
- Molecular formula:C₂₂₁H₃₄₂N₄₆O₆₈
- Sample size:100 mg
- MOQ:1 g
- Appearance:White to almost white powder
- Solubility:Freely soluble in water, practically insoluble in acetonitrile.
- Clarity and color:Clear and colorless liquid
- Assay:95% ~ 105%
- pH:6.0 - 9.0
- Packaging:Aluminum foil bag or HDPE bottle
- Storage:Long-term -20°C; Short-term 2–8°C
- Manufacturing Site:Shaoxing, Zhejiang, China
Therapeutic AreasA Game Changer in Obesity PharmacotherapyThis review synthesizes findings from preclinical and clinical studies, highlighting retatrutide’s mechanisms, efficacy, and safety profile. Retatrutide’s unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes. Animal studies demonstrate retatrutide’s ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies. Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease. Common adverse effects are primarily gastrointestinal and dose-related. Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide’s long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BMI reduction warrant further investigation. Retatrutide heralds a new era in obesity and T2DM treatment, offering hope for improved patient outcomes.
Outlook & DevelopmentTreatment with retatrutide was associated with improvements in cardiometabolic measures (exploratory endpoints) including systolic and diastolic blood pressure, triglycerides, LDL-cholesterol, total cholesterol, HbA1c, and fasting glucose and insulin at weeks 24 and 48."We believe that combining glucagon receptor agonism with GIP and GLP-1 receptor agonism may be one of the reasons retatrutide showed this level of weight reduction," said Dan Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories. Retatrutide appears to herald a significant advancement in the realm of pharmacotherapy for obesity and weight management. With its remarkable safety profile and noteworthy percentages of weight reduction, it undeniably generates considerable enthusiasm within the medical community. However, it is essential to emphasize that additional phase 3 clinical trials are crucial to further evaluate the drug’s safety and long-term effects.
